ArticleNature communications2026
3D triply periodic minimal surface gyroid hydrogel scaffolds for soft tissue engineering.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Engineering functional soft tissue constructs remains difficult because scaffolds must meet the mechanical, physicochemical, and biological requirements simultaneously. Here, we present a cell-laden hydrogel gyroid scaffold designed to support vascularisation, long-term multicellular culture, and implantation for the development of 3D tissue constructs. The scaffold is structurally optimised to balance nutrient transport and mechanical stability, and is fabricated with high fidelity by mitigating cell-induced light scattering. The gyroid architecture supports the formation of dense microvascular networks throughout the 3D construct, and its curved Gaussian curvature promotes endothelial self-assembly. The scaffold also enables high-density co-culture of HepG2 cells and HUVECs without active perfusion, resulting in a vascularised 3D liver tumour model with enhanced tissue-specific function. Upon subcutaneous implantation in mice, the constructs show enhanced neovascularisation and facilitate tumour formation. These findings identify the gyroid scaffold as a biologically favourable architecture for generating bulk vascularised constructs, with potential applications in disease modelling, drug screening and regenerative medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.